These press releases are for business and financial media.
-
- 15 December 1999
- ASTRAZENECA SUBMITS FIRST REGULATORY APPLICATION FOR ITS NEW ASTHMA MEDICATION SYMBICORT® VIA EUROPEAN MUTUAL RECOGNITION AstraZeneca today announced that the regulatory application for Symbicort®, budesonide and formoterol in a single inhaler (Turbuhaler®) for maintenance therapy in asthma, has been submitted to the authorities in Sweden as the first step in the European Union's mutual recognition procedure. Applications for the new product will follow in early 2000 in further countries.
-
- 13 December 1999
- ZENECA AGROCHEMICALS AND CAMBRIDGE DISCOVERY CHEMISTRY ANNOUNCE COLLABORATION Cambridge Discovery Chemistry, formerly Cambridge Combinatorial, a wholly owned subsidiary of Oxford Molecular Group plc, and Zeneca Agrochemicals, the crop protection and plant science business of AstraZeneca, today (13th December) announced a major chemistry R&D collaboration.
-
- 06 December 1999
- APPENDIX: ASTRAZENECA R&D PIPELINE Download R&D Pipeline (96k Acrobat file .pdf)
-
- 06 December 1999
- ASTRAZENECA PROGRESSES KEY PRODUCTS AND AIMS TO DOUBLE PRODUCT PORTFOLIO VALUE EVERY FIVE YEARS HIGHLIGHTS
-
- 06 December 1999
- HIGHLIGHTS: ASTRAZENECA's FIRST PHARMACEUTICALS R&D PRESENTATION Download presentation (142k Acrobat file .pdf)
-
- 17 November 1999
- ASTRAZENECA ENTITLED TO INTERLOCUTORY* INJUNCTION TO PREVENT MARKETING OF A GENERIC VERSION OF OMEPRAZOLE IN ISRAEL AstraZeneca today announced that the Tel Aviv District Court has held that AstraZeneca is entitled to an interlocutory injunction in Israel based on the formulation patent, to prevent Dexcel Ltd. from marketing a generic omeprazole product.
-
- 16 November 1999
- ZENECA AGROCHEMICALS ANNOUNCES INVESTMENT IN MESOTRIONE CORN HERBICIDE Zeneca Agrochemicals today (16 November) announced its decision to invest $47 million in the formulation and manufacture of the new corn herbicide active ingredient mesotrione, to be produced at Zeneca's manufacturing facility at Cold Creek, Alabama, USA.
-
- 12 November 1999
- ASTRAZENECA - INTERLOCUTORY INJUNCTION TO PREVENT MARKETING OF A GENERIC OMEPRAZOLE PRODUCT IN GERMANY DENIED AstraZeneca today announced that its request for an interlocutory injunction in Germany to prevent Azupharma GmbH from marketing a generic omeprazole version has been denied by the Appeal Court in Frankfurt. Omeprazole is the substance used in Losec®.
-
- 28 October 1999
- ASTRAZENECA NINE MONTHS RESULTS, 1999 Commentary (51k PDF file .pdf) Figures (82k PDF file .pdf)
-
- 27 October 1999
- ASTRAZENECA DIVESTS TWO CARDIOVASCULAR MEDICINES IN SCANDINAVIAN AND EUROPEAN MARKETS TO COMPLY WITH EC MERGER CONDITIONS AstraZeneca today announced the partial divestment of two cardiovascular medicines, in Scandinavian and European markets, to comply with European Commission merger conditions set in approving the merger of Astra, of Sweden, and Zeneca, of the UK, earlier this year.
-
- 21 October 1999
- ASTRAZENECA SUBMITS FIRST REGULATORY APPLICATION FOR ITS NEW PPI VIA EUROPEAN MUTUAL RECOGNITION AstraZeneca today announced that a regulatory application for H199/18, a new proton pump inhibitor (PPI), has been submitted to authorities in Sweden, acting as rapporteur country in the European Union's mutual recognition procedure. The new pharmaceutical contains the active substance esomeprazole.
-
- 18 October 1999
- ASTRAZENECA's OMEPRAZOLE FORMULATION PATENTS AstraZeneca today announced that the Tel Aviv District Court has upheld the formulation patents for omeprazole. This follows an appeal by AstraZeneca and the Israeli company Unipharm. The District Court found that the inventions subject to the patents constituted a significant advance over prior art and that they were not obvious. Omeprazole is the substance used in Losec®.
-
- 04 October 1999
- ASTRAZENECA EXPANDS ACCESS TO INCYTE DATABASES AND BECOMES THE FIRST SUBSCRIBER TO INCYTE's LIFEEXPRESS RNA AND PROTEIN EXPRESSION DATABASE PROGRAM Zeneca and Incyte Pharmaceuticals, Inc. of Palo Alto, California announced today that AstraZeneca has expanded its access to Incyte's databases and will become the first subscriber to Incyte's LifeExpress™ expression database program.
-
- 20 September 1999
- ACCOLATE APPROVED BY FDA FOR CHILDREN WITH ASTHMA SEVEN YEARS OF AGE AND OLDER A new paediatric formulation of the popular asthma medication, 'Accolate' has received approval from the U.S. Food and Drug Administration (FDA) for use in patients as young as seven years of age. The product will be available in a 10-milligram, non-flavored mini-tablet specifically designed for children. Recommended dosing is one 10-mg mini-tablet twice daily, even during symptom free periods.
-
- 13 September 1999
- NEW TABLET PRODUCTION FACILITY IN GERMANY TO ENSURE FUTURE PRODUCT GROWTH AstraZeneca announced today a $35 million investment in a new tablet production facility at its Plankstadt site in Germany. This plant, scheduled to start operating in 2002, will initially manufacture 'Casodex', a treatment for prostate cancer which is now the number one selling anti-androgen worldwide, and 'Zomig', a new treatment for migraine headache with or without aura, which is now launched in over 45 countries worldwide. The design of the new facility incorporates an enhanced capability for process
-
- 09 September 1999
- ASTRAZENECA TO APPEAL DENIAL OF OMEPRAZOLE INTERLOCUTORY INJUNCTIONS IN GERMANY AstraZeneca today announced it will appeal against a decision, not yet received in written form, by the District Court in Munich not to grant AstraZeneca's request for preliminary injunctions to prevent CT-Arzneimittel GmbH and Stadapharm GmbH to continue to sell generic omeprazole products in Germany. The decision was based on procedural grounds. The reasons given by the Court were that AstraZeneca had not filed the requests for preliminary injunctions soon enough after these generic products were put on
-
- 02 September 1999
- ASTRAZENECA LAUNCHES NEW TREATMENT FOR MIGRAINE, 'Zomig', IN CHINA AstraZeneca has taken an important step in developing further its business in China by launching 'Zomig', a new oral treatment for acute migraine.
-
- 23 August 1999
- ASTRAZENECA GRANTED COORDINATION OF PRILOSEC® US PATENT CASES AstraZeneca today announced that the Judicial Panel on Multidistrict Litigation has ordered that all pending patent infringement cases in the United States relating to omeprazole should be coordinated for pretrial proceedings in the District Court of Southern District of New York.
-
- 19 August 1999
- ASTRAZENECA - INTERLOCUTORY INJUNCTION IN GERMANY TO PREVENT MARKETING OF A GENERIC OMEPRAZOLE PRODUCT UPHELD AstraZeneca today announced that an Appeal Court has upheld a previously granted interlocutory injunction in Germany based on AstraZeneca's formulation patents. The injunction prevents Ratiopharm GmbH and Merckle GmbH from marketing a generic omeprazole product. Omeprazole is the substance used in Losec®.
-
- 15 August 1999
- ARIMIDEX CHALLENGES TAMOXIFEN AS GOLD STANDARD TREATMENT IN WOMEN WITH ADVANCED POST-MENOPAUSAL BREAST CANCER For the last 25 years the 'gold standard' treatment for women with breast cancer has been tamoxifen. New data presented today at the 10th European Cancer Conference in Vienna, Austria, challenges this dominant position. 'Arimidex', a selective non-steroidal aromatase inhibitor, has been shown to be at least as effective and well-tolerated as tamoxifen and, in one of the two international studies reported, the data indicate that 'Arimidex' is more effective.
-
- 15 August 1999
- STUDY OFFERS NEW APPROACH FOR INFANTS AND YOUNG CHILDREN WITH ASTHMA Once-daily use of nebulized budesonide improves asthma control in newly published pediatric study
-
- 03 August 1999
- ASTRAZENECA 1999 HALF YEAR RESULTS, 3 August 1999 Commentary (32k Acrobat file .pdf)
-
- 08 July 1999
- ASTRAZENECA WINS INTERLOCUTORY* INJUNCTION IN GERMANY TO PREVENT MARKETING OF A GENERIC VERSION OF OMEPRAZOLE AstraZeneca today announced that it has been granted an interlocutory injunction in Germany based on the formulation patents to prevent Ratiopharm GmbH and Merckle GmbH from marketing a generic omeprazole product. Omeprazole is the substance used in Losec®.
-
- 30 June 1999
- ASTRAZENECA COMPLETES SALE OF ZENECA SPECIALTIES AstraZeneca today completed the previously announced sale of its Zeneca Specialties business for a cash amount of $2.1 billion (£1.3) in a buyout jointly financed by Cinven and Investcorp.
-
- 22 June 1999
- ASTRAZENECA LAUNCHES CASODEX 150mg AstraZeneca today announced the first European product launch for the new company. 'Casodex' 150 mg, a single daily tablet for the treatment of prostate cancer, is now available in the UK, the first market world-wide in which this new presentation has been introduced. It is indicated for the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable. Further launches are anticipated during
-
- 16 June 1999
- ASTRAZENECA AGREES TO VOTE ITS SUGEN SHARES IN SUPPORT OF PHARMACIA & UPJOHN MERGER PROPOSAL AstraZeneca PLC today announced it had agreed to vote the Group's approximately 20 per cent shareholding in SUGEN, Inc., a Californian-based biotechnology company, in favour of the recently announced Pharmacia & Upjohn (P&U) and SUGEN merger proposal.
-
- 16 June 1999
- ASTRAZENECA's CARDIOVASCULAR FRANCHISE FURTHER COMPLEMENTED BY MARKETING DEAL WITH KNOLL AstraZeneca PLC today signed an agreement with Knoll AG - the pharmaceuticals arm of BASF Pharma - for the marketing of Reductil (sibutramine), an obesity management treatment, in Europe and other territories.
-
- 16 June 1999
- CORRECTION TO EARLIER PRESS RELEASE: ASTRAZENECA TO VOTE ITS SUGEN SHARES IN SUPPORT OF PHARMACIA & UPJOHN MERGER PROPOSAL Please see correction to share price in 2nd paragraph.
-
- 16 June 1999
- GENERIC CHALLENGE TO LOSEC WITHDRAWN IN CANADA The patent protection for omeprazole, the active substance in Losec, expires in Canada in July 1999. However, due to national patent legislation, in Canada the opportunity for generic competition to Losec has existed since 1996 through compulsory licensing under AstraZeneca's substance patent. AstraZeneca has several other patents approved in Canada, including a formulation patent.
-
- 16 June 1999
- NEW £31 MILLION PLANT OPENING UNDERLINES SUCCESS OF ANTI-CANCER DRUG, "ZOLADEX" Sir David Barnes, Deputy Chairman of AstraZeneca, today opened a new £31 million manufacturing plant for the anti-cancer drug 'Zoladex', at AstraZeneca's Macclesfield site.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 09:15 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
